Vistagen FY2024 net loss narrows to $29.4M; fasedienol Phase 3 program on track

Vistagen Therapeutics, Inc.

Net loss of $29.4M for FY2024, down from $59.2M in FY2023; cash and equivalents $119.2M as of March 31, 2024.
R&D expenses decreased to $20.0M from $44.4M, primarily due to timing of fasedienol Phase 3 trials.
PALISADE-3 Phase 3 trial for fasedienol in SAD initiated; PALISADE-4 expected in 2H 2024; positive PALISADE-2 results previously.
Appointed Cindy Anderson as CFO; entered exclusive negotiation with Fuji Pharma to develop PH80 in Japan for menopausal hot flashes.
Completed underwritten public offering to fund pipeline milestones; itruvone Phase 2B planning underway for MDD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.